Expressions of EphA2-ephrinA1 and CD105 in Human Astrocytoma and Their Relationship with Prognosis

LIU Liqiang; FANG Yanwei; WENG Jiehui; QIU Wenna; GENG Shaomei; JIAO Baohua

doi:10.3971/j.issn.1000-8578.2014.06.016

Cancer Research on Prevention and Treatment > 2014 > 41(06): 582-587. > DOI: 10.3971/j.issn.1000-8578.2014.06.016

LIU Liqiang, FANG Yanwei, WENG Jiehui, QIU Wenna, GENG Shaomei, JIAO Baohua. Expressions of EphA2-ephrinA1 and CD105 in Human Astrocytoma and Their Relationship with Prognosis[J]. Cancer Research on Prevention and Treatment, 2014, 41(06): 582-587. DOI: 10.3971/j.issn.1000-8578.2014.06.016

Citation:

PDF (1213 KB)

Expressions of EphA2-ephrinA1 and CD105 in Human Astrocytoma and Their Relationship with Prognosis

Department of Neurosurgery, The Second Hospital of Hebei Medical University, Shijiazhuang050000, China

More Information

Received Date: May 20, 2013
Revised Date: December 24, 2013

Abstract

Abstract

Objective To investigate the expressions of tyrosine kinase receptor EphA2 and ligand ephrinA1 in human astrocytoma and their correlations with prognosis. Methods Expression levels of EphA2 and ephrinA1 were detected by immunohistochemical assay in 55 cases of surgically resected human astrocytoma tissues and 15 cases of normal brain tissues. CD105-stained microvessel density (MVD) in microvascular endothelial cells were also measured. Results Expressions of EphA2(51/55) and CD105-MVD (34.26±12.61) in human astrocytomas were signifi cantly higher than those in normal brain tissues(P<0.01). With the increased pathology grade of human astrocytomas, ephrinA1 expression was decreased; CD105-MVD was significantly positively correlated with EphA2 expression (r=0.713, P<0.01), and significantly negatively correlated with ephrinA1 expression (r=－0. 772, P<0.01). EphA2 was signifi cantly negatively correlated with ephrinA1 expression (r=－0.912, P<0.01). EphA2, CD105-MVD and ephrinA1 were all important risk factors for astrocytomas prognosis. Overall and progression-free survival of patients with positive EphA2 and CD105-MVD and negative ephrinA1 was signifi cantly shorter than those with all positive EphA2, CD105-MVD and ephrinA1, all negative EphA2, CD105-MVD and ephrinA1, or negative EphA2 and CD105-MVD and positive ephrinA1. Conclusion EphA2 and CD105-MVD are specifically up-regulated and ligand ephrinA1 is specifi cally down-regulated in astrocytomas and may be closely involved in the poor prognosis. EphA2 and ephrinA1 could be the new targets for diagnosis, therapeutic and prognosis evaluation of human brain astrocytomas.
- Astrocytomas,
- EphA2,
- EphrinA1,
- CD105,
- MVD,
- Survival analysis,
- Prognosis

FullText(HTML)

References (15)

References

[1]	Korkolopoulou P,Patsouris E,Kavantzas N,et al.Prognostic implications of microvessel morphometry in diffuse astrocytic neoplasms[J].Neuropathol Appl Neurobiol,2002,28(1):57-66.
[2]	Merritt WM, Kamat AA, Hwang JY, et al. Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer[J]. Cancer Biol Ther,2011,10(12):1306-14.
[3]	Weidner N. Current pathologic methods for measuring intratumoral microvessel density with in breast carcinoma and other solid tumors[J]. Breast Cancer Res Treat,1995,36(2):169-80.
[4]	Wang LF, Fokas E, Bieker M, et al. Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients[J].Oncol Rep, 2008,19(1):151-6.
[5]	Li X, Wang L, Gu JW, et al. Up-regulation of EphA2 and down regulation of EphrinA1 are associated with the aggressive phenotype and poor prognosis of malignant glioma[J]. Tumour Biol,2010,31(5):477-88.
[6]	Xu JS, Zhang JX, Geng TH, et al. Expression of EphA2 and ephrinA1 in human renal cell carcinoma and its relationship with angiogenesis[J]. Zhonghua Zhong Liu Za Zhi, 2009, 31 (6):438-41.[徐金升,张俊霞,耿同会,等.肾癌中EphA2和 EphrinA1的表达及其与微血管密度的关系[J]. 中华肿瘤杂志,2009, 31(6):438-41.]
[7]	Wykosky J, Palma E, Gibo DM, et al. Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor[J]. Oncogene,2008, 27(58):7260-73.
[8]	Li X,Li AM,Wang L, et al. Relationship of EphA2 gene expression with pathologic grade proliferation and apoptosis of brain actrocytic tumors[J]. Zhonghua Shen Jing Wai Ke Za Zhi, 20 08,24(11):818-21.[李侠,李安民,王莉,等.EphA2基因在脑星形胶质细胞瘤的表达[J].中华神经外科杂志,2008,24(11): 818- 21.]
[9]	Herrem CJ, Tatsumi T, Olson KS, et al. Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma[J].Clin Cancer Res,2005,11 (1):226-31.
[10]	Wang D,Qi FJ. Expression of EphA2 and E-cadherin in breast cancer and their relationship with prognosis[J]. Zhongguo Zu Zhi Hua Xue Yu Xi Bao Hua Xue Za Zhi,2010,19(1):66-71.[王丹,齐凤杰. EphA2和E-cadherin在乳腺癌中的表达及其与患者预后的关系[J]. 中国组织化学与细胞化学杂志,2010,19(1):66-71.]
[11]	Fang YW, Qiu WN, Geng SM, et al. Correlation of both EphA2- ephrinA1 and tumorigenesis and targeted therapy potency[J]. Zhong Liu Fang Zhi Yan Jiu,2012,39(6):750-3. [方艳伟,邱文娜, 耿少梅,等.EphA2-ephrinA1与恶性肿瘤发生的关系及靶向治疗潜能探讨[J].肿瘤防治研究,2012,39(6):750-3.]
[12]	Wu D,Li SS,Qiao YH, et al. Expressions of EphA2 gene in squamous cell cervical carcinoma and effect on prognosses[J]. Zhengzhou Da Xue Xue Bao(Yi Xue Ban), 2004,39(3):381-5. [吴丹,李珊珊,乔玉环,等.宫颈鳞癌组织中EphA2基因的表达[J].郑州大学学报(医学版),2004,39(3):381-5.]
[13]	Wang YF,Ding YL,Shi GS, et al. Expression and correlation of TGF-β1 and CD105 in glioma tissues[J].Zhong Liu Fang Zhi Yan Jiu, 2007,34(12):932-4,987.[王艳芬,丁永玲,施公胜,等. 脑胶质瘤组织中TGF-β1和CD105蛋白表达及其相关性[J]. 肿瘤防治研究,2007,34(12):932-4,987.]
[14]	Zhang XF,Liu YM,Liu LQ, et al. The Detective Significance of Microvascular Density in Non-Small-Cell Lung Cancer and Esophageal Carcinoma[J].Zhong Liu Ji Chu Yu Lin Chuang, 20 11,24(2):109-11.[张晓飞,刘艳梅,刘立群,等. 非小细胞肺癌和食管癌微血管密度的检测意义[ J ] .肿瘤基础与临床,2011,24(2):109-11.]
[15]	Zhu Y,Yang QC,Liu HB, et al. Expression and signifi cance of HIF- 1& alpha;and CD105 in cervix carcinoma tissues[J]. Zhonghua Bing Li Xue Za Zhi,2008,37(4):264-5.[朱燕,杨其昌,刘宏斌,等.人缺氧诱导因子1α与CD105在宫颈癌中的表达及意义[J].中华病理学杂志,2008,37(4):264-5.]

[1]	HU Zhen, LI Shengjin. Survival and Prognosis of Primary Mediastinal and Pulmonary Sarcoma Based on SEER Database[J]. Cancer Research on Prevention and Treatment, 2023, 50(11): 1091-1096. DOI: 10.3971/j.issn.1000-8578.2023.23.0419
[2]	LI Baozhong, LIU Shiwei, ZHANG Yufen, HE Ming, CHEN Xin, ZHU Hui, XU Xinjian, LI Fei. Prognosis and 5-year Follow-up of 213 Cases of StageⅢB Adenocarcinoma Patient of Esophagogastric Junction Treated by Surgery[J]. Cancer Research on Prevention and Treatment, 2015, 42(10): 1001-1004. DOI: 10.3971/j.issn.1000-8578.2015.10.011
[3]	LV Minhao, QIN Li, LI Juntao, GUO Xuhui, LIU Fawen, CUI Shude, ZHANG Hengwei. 原发性乳腺癌分子分型与新辅助化疗疗效及预后的相关性[J]. Cancer Research on Prevention and Treatment, 2015, 42(08): 782-788. DOI: 10.3971/j.issn.1000-8578.2015.08.007
[4]	MAO Zhiyuan, XIONG Mei, REN Li, LI Dechang, YUE Ying, ZHENG Jichun. Pathological Factors for Prognosis of Extrahepatic Cholangiocarcinoma[J]. Cancer Research on Prevention and Treatment, 2014, 41(07): 777-780. DOI: 10.3971/j.issn.1000-8578.2014.07.019
[5]	Li Suyi, Zhou Jian, Song Yongping, Zhao Huifang, Zhang Yanli, Zuo Wenli, Wei Xudong, Li Yufu, Zhu Xinghu, Fang Baijun. Analysis of Clinical Characteristics of Granulocytic Sarcoma from Twenty-eight Cases[J]. Cancer Research on Prevention and Treatment, 2013, 40(03): 273-277. DOI: 10.3971/j.issn.1000-8578.2013.03.013
[6]	CHI Zhi-hong, SHENG Xi-nan, LI Si-ming, CUI Chuan-liang, SI Lu, GUO Jun. A Clinical Characters and Prognosis Analysis on 357 Cases with Cutaneous Malignant Melanoma in China[J]. Cancer Research on Prevention and Treatment, 2011, 38(11): 1316-1319. DOI: 10.3971/j.issn.1000-8578.2011.11.025
[7]	ZHU Hai-sheng, YANG Yun-li, ZHAO Dan, LIU Ying-xin, ZHU Xiao-dong. Prognostic Factors of Elderly Nasopharyngeal Carcinoma: A Report of 171 Cases[J]. Cancer Research on Prevention and Treatment, 2011, 38(03): 281-285. DOI: 10.3971/j.issn.1000-8578.2011.03.011
[8]	WANG Yu-xiang, ZHU Shu-chai, SU Jing-wei, LI Juan, SHEN Wen-bin. Prognostic Analysis of Three-dimensional Conformal Radiotherapy (3D-CRT) for Cervical and Upper-thoracic Esopageal Cancer[J]. Cancer Research on Prevention and Treatment, 2011, 38(01): 93-97. DOI: 10.3971/j.issn.1000-8578.2011.01.027
[9]	SUN Fa-lin, BU Shi-chong, MA Ke, LI Qing-yun. Retrospectively Analysis of Prognostic Correlative Factors of Aryngeal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2009, 36(05): 405-408. DOI: 10.3971/j.issn.1000-8578.2009.05.012
[10]	SUN Xi-bin, DUAN Weng-jie, WANG Jing-p ing, et al, . Analysis of Cox Model for Clinical Pathology Factors with Prognosis in Colorecatal Cancer[J]. Cancer Research on Prevention and Treatment, 2001, 28(05): 383-384. DOI: 10.3971/j.issn.1000-8578.970

Cited By

JIAO Baohua

Department of Neurosurgery, The Second Hospital of Hebei Medical University, Shijiazhuang050000, China

Get Citation

PDF

XML

Article views (1773) PDF downloads (637)

Turn off MathJax

Article Contents

Abstract

References

Expressions of EphA2-ephrinA1 and CD105 in Human Astrocytoma and Their Relationship with Prognosis

Abstract

References

Related Articles

Catalog

JIAO Baohua

Download Center

Links

Contact Us

Expressions of EphA2-ephrinA1 and CD105 in Human Astrocytoma and Their Relationship with Prognosis

Abstract

References

Related Articles

Catalog

JIAO Baohua

Download Center

Links

Contact Us

Export File

Citation

Format

Content